Targeting TSP-1 may constitute a therapeutic approach in patients carrying mutations affecting proper folding of dysferlin since it would reduce inflammation and avoid the undesirable side-effects reported in patients with dysferlinopathy treated with prednisone. This evidence concerns the gene DYSF and neuromuscular disease caused by qualitative or quantitative defects of dysferlin.